TIGIT and breast carcinoma: A study on breast cancer patients with liver or brain metastases who responded poorly to anti-PD-1 therapy found that targeting LAG3 in combination with other co-inhibitory receptors, such as TIGIT, represents a potential therapeutic strategy for tumors with low PD-1 expression [35].